Preclinical studies demonstrated its exceptional potency and specificity (IC50 < 2 nM, ~700–1000-fold selectivity over KRAS WT) and induced significant tumor regression in xenograft and immunocompetent mouse models [17,18]. The gene discussed is KRAS; the disease is neoplasm.